(UroToday.com) In the first interim analysis of the randomized, multicenter, open-label, phase 3 KEYNOTE-426 study, treatment with pembrolizumab + axitinib significantly improved OS, PFS, and ORR versus sunitinib monotherapy in treatment-naive advanced clear cell RCC.1 Extended follow-up (median, 30.6 months) continued to demonstrate the superior efficacy of pembrolizumab + axitinib versus sunitinib monotherapy in this patient population.2 At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting’s oral abstract session, Dr. Brian Rini and colleagues presented results of the prespecified final analysis with a 42.8-month median follow-up and a 35.6-month minimum follow-up.